Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.83 |
| ▸ | POLB | P06746 | 2/20 | 0.83 |
| ▸ | APEX1 | P27695 | 2/20 | 0.83 |
| ▸ | RECQL | P46063 | 2/20 | 0.83 |
| ▸ | POLH | Q9Y253 | 2/20 | 0.83 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.83 |
| ▸ | MEN1 | O00255 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | MMP1 | P03956 | 1/20 | 0.75 |
| ▸ | GAA | P10253 | 1/20 | 0.75 |
| ▸ | HTT | P42858 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.72 |
| ▸ | TUBB | P07437 | 1/20 | 0.72 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18130384 | 0.91 | ABCB1 (0.83) | ABCB1CYP3A4CYP2D6KDM4EPOLB | |
| Isokaempferide SCHEMBL1628023 | 0.91 | POLH (1.00) | ABCB1CYP3A4CYP2D6KDM4EPOLB | |
| Isokaempferide SCHEMBL29721227 | 0.91 | POLH (1.00) | ABCB1CYP3A4CYP2D6KDM4EPOLB | |
| SCHEMBL28664486 | 0.88 | ABCB1 (0.79) | ABCB1CYP3A4CYP2D6KDM4EPOLB | |
| Ermanin SCHEMBL2875089 | 0.88 | CYP3A4 (1.00) | ABCB1CYP3A4CYP2D6KDM4EPOLB | |
| SCHEMBL20100897 | 0.88 | ABCB1 (0.79) | ABCB1CYP3A4CYP2D6KDM4EPOLB | |
| SCHEMBL11096105 | 0.87 | POLH (0.83) | ABCB1CYP3A4CYP2D6KDM4EPOLB | |
| SCHEMBL15361036 | 0.87 | POLH (0.83) | ABCB1CYP3A4CYP2D6KDM4EPOLB | |
| SCHEMBL3188065 | 0.87 | POLH (0.83) | ABCB1CYP3A4CYP2D6KDM4EPOLB | |
| SCHEMBL28119670 | 0.86 | ABCB1 (0.76) | ABCB1CYP3A4CYP2D6KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051551-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2025-02-13 | — | — | US | claimed |
| CN-117561081-A | Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia | 广州珍实视界生物医药科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| CN-113069442-A | Novel application of galangin and derivatives thereof | 广东省农业科学院动物卫生研究所 | 2021-07-06 | — | — | CN | claimed |
| CN-112522195-A | Micro RNA, inhibitor and application in-vitro culture of natural killer cells | 张文化 | 2021-03-19 | — | — | CN | claimed |
| WO-1996031206-A2 | FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-10-10 | — | — | WO | claimed |
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| CN-120585818-A | Application of galangin-3-methyl ether in preparation of medicine for treating or preventing pathologic cardiac hypertrophy | 江南大学 | 2025-09-05 | — | — | CN | disclosed |
| US-20250169516-A1 | METHODS, DEVICES AND COMPOSITIONS FOR PRESERVING HUMAN MILK | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-05-29 | — | — | US | disclosed |
| US-12239142-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| US-20250051551-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2025-02-13 | — | — | US | disclosed |
| US-12163004-B2 | Polymer composites | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240355451-A1 | METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY | NESTLE SA (CH) | 2024-10-24 | — | — | US | disclosed |
| WO-2007110801-A2 | COMPOSITIONS AND METHODS TO ADD VALUE TO PLANT PORDUCTS, INCREASING THE COMMERCIAL QUALITY, RESISTANCE TO EXTERNAL FACTORS AND POLYPHENOL CONTENT THEREOF | LESCHOT SANHUEZA ANDRES ANTONI (CL) | 2007-10-04 | — | — | WO | disclosed |
| US-20070232495-A1 | Compositions and methods to add value to plant products, increasing the commercial quality, resistance to external factors and polyphenol content thereof | NAPPA ALVARO O | 2007-10-04 | — | — | US | disclosed |
| CN-1958057-A | Application of extractive of Daliangjiang, and application in medication | HONGYI TECH CO LTD NANCHANG (CN) | 2007-05-09 | — | — | CN | disclosed |
| US-20070098825-A1 | Compositions containing Phaseolus vulgaris extract and Alpinia officinarum extract for the prevention and treatment of obesity and type II diabetes | S.I.I.T. S.R.L. SERVISIO INTERNAZIONALE IMBA;;AGGI TERMOSALDANTI (IT) | 2007-05-03 | — | — | US | disclosed |
| CN-1799616-A | Gastric ulcer treatment medicine, its preparation process and application | SHENZHEN DONGFANG TAIGE BIOPHA (CN) | 2006-07-12 | — | — | CN | disclosed |
| EP-1212313-B1 | 7-CARBOXY-FLAVONE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE | NEGMA LERADS (FR) | 2003-05-28 | — | — | EP | disclosed |
| WO-1996031206-A2 | FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-10-10 | — | — | WO | disclosed |
| WO-1996010408-A1 | CARDIOACTIVE COMPOUNDS ISOLATED FROM WOODY PERENNIALS | THE EXECUTIVE DIRECTOR OF THE WESTERN AUSTRALIAN DEPARTMENT OF CONSERVATION AND LAND MANAGEMENT (AU) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | LPL, CEL, LPO | ABCB1 4482/4885CYP3A4 1678/4885CYP2D6 1312/4885 |
| US-20070232495-A1 | Compositions and methods to add value to plant products, increasing the commercial quality, resistance to external factors and polyphenol content thereof | C5, PNN, NQO1 | ABCB1 3107/4885CYP3A4 843/4885CYP2D6 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.